The European Regenerative Medicines Market was valued at USD 5.06 billion in 2020 and is expected to reach USD 13.56 billion by 2025, growing at a CAGR of 21.80% during the forecast period.
The European nation has strong biotechnology sectors in the UK & Germany countries. Increasing support from the government & private sectors is driving the demand for the regenerative medicine market. According to the Alliance for Regenerative Medicine, there are around 400+ companies of regenerative medicines in Europe. Adoption of the computational tools in the healthcare industry will accelerate the growth rate of the market. Bioinformatics tools provide high-resolution data, algorithms & strategies for regenerative medicines. According to the World Health Organization, there are 60 million people are diagnosed with diabetes in the European region. An increasing number of patients with diabetes is surging the growth of the regenerative medicine market in Europe.
Increasing aging population, a growing number of lifestyle disorders (diabetes, obesity), rising advancements in the research & development, an increasing number of people suffering from chronic disorders (such as liver diseases, blood disorders), and growing involvement of government to help research institutes for the development of regenerative medicines are driving the growth of regenerative medicines market in Europe.
However, the presence of uncertain regulatory guidelines and stringent ethical laws to conduct research & developments in tissue-engineered products & cell-based products are restraining the growth of the regenerative medicines market in Europe.
This research report segmented and sub-segmented into the following categories:
Regional Analysis
The regenerative medicines market in the UK is ruling with dominant shares of the market. Support from the government through investments in the development of innovative products is boosting up the growth of the market. On-going research and development may also impact positively on the growth of the market.
Germany Regenerative Medicines Market is next to the UK is leading the highest shares of the European market by owing to the increasing incidences of chronic diseases. Prevalence of quality treatment procedures is propelling the demand of the market.
Notable companies operating in the Europe Regenerative Medicines Market Vertex Pharmaceuticals Incorporated, Acelity L.P. Inc., Celgene Corporation, StemCells, Inc., Organogenesis Inc., NuVasive, Inc., Vericel Corporation (Genzyme), Japan Tissue Engineering Co., Ltd., Cytori Therapeutics Inc., Advantagene, Inc. and Mesoblast Ltd. (Australia).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Product
5.2.1 Introduction
5.2.2 Cell-Based Products
5.2.2.1 Autologous Cell-Based Products
5.2.2.2 Allogeneic Cell-Based Products
5.2.3 Acellular Products
5.3 Therapy
5.3.1 Introduction
5.3.2 Cell Therapy
5.3.3 Gene Therapy
5.3.4 Tissue Engineering
5.3.5 Immunotherapy
5.4 Application
5.4.1 Introduction
5.4.2 Orthopedic & Musculoskeletal Spine
5.4.3 Dermatology
5.4.4 Cardiovascular
5.4.5 Central Nervous System
5.4.6 Oncology
5.4.7 Diabetes
5.4.8 Other Applications
6. Geographical Analysis
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Vertex Pharmaceuticals Incorporated (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Acelity L.P. Inc. (U.S.)
8.3 Celgene Corporation (U.S.)
8.4 StemCells, Inc. (U.S.)
8.5 Organogenesis Inc. (U.S.)
8.6 NuVasive, Inc. (U.S.)
8.7 Vericel Corporation (Genzyme) (U.S.)
8.8 Cytori Therapeutics Inc. (U.S.)
8.9 Advantagene, Inc. (U.S.)
8.10 Mesoblast Ltd. (Australia)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports